| Literature DB >> 20028817 |
Neil Benson1, Joost de Jongh, Jonathan D Duckworth, Hannah M Jones, Henry E Pertinez, Jaiessh K Rawal, Tamara J van Steeg, Piet H Van der Graaf.
Abstract
Recombinant alpha interferon (IFN-alpha) is used in the treatment of hepatitis C virus (HCV)-infected patients but is not optimal in terms of efficacy or tolerability. Toll-like 7 receptor (TLR-7) agonists stimulate the innate immune system to produce, among other cytokines, IFN-alpha and are being evaluated as alternative drugs to treat HCV infection. This paper describes the application of pharmacokinetic-pharmacodynamic (PK-PD) modeling to understanding the behavior of a TLR-7 agonist [9-benzyl-8-hydroxy-2-(2-methoxyethoxy) adenine (BHMA)] in mice, using IFN-alpha as a biomarker. This is the first report of such a PK-PD model, and the conclusions may be of utility in the clinical development of TLR-7 agonists for HCV infection.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20028817 PMCID: PMC2825998 DOI: 10.1128/AAC.00551-09
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191